COMMUNIQUÉS West-GlobeNewswire

Black Bird Biotech Announces New CEO; Provides Commentary on Refreshed Path
16/04/2024
Disruptive Biotech Firm Appoints Public Markets Veteran Nelson Grist as its Chief Executive Officer and Future Member of its Board of Directors ARGYLE, TX, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Black [...]
ProPhase Labs Unveils Project ZenQ-AI
16/04/2024
Leveraging ProPhase Labs’ AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc [...]
Excision BioTherapeutics Announces Oral Presentation of HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24 2024
16/04/2024
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious latent viral [...]
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
16/04/2024
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Priority Original [...]
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
16/04/2024
MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March [...]
REPEAT – MEDIA ADVISORY: Press conferences with patients who have been charged user fees of hundreds or even thousands of dollars at for-profit surgery clinics
16/04/2024
TORONTO and LONDON and WATERLOO and BRAMPTON, Ontario, April 16, 2024 (GLOBE NEWSWIRE) -- Patients are being threatened with extremely long wait times, denied vital procedure information, and coerced or manipulated into [...]
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
16/04/2024
Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changes Presentation to be featured during AAN Emerging Science Session Company on track to [...]
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
16/04/2024
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors SALT LAKE CITY, [...]
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
16/04/2024
Data Presented at the American College of Cardiology Scientific Sessions; Research Letter Published in the Prestigious American Heart Journal Oak Ridge, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: [...]
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
16/04/2024
Names Ed Pershing as Chief Executive Officer and Dominic Rodrigues as President KNOXVILLE, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today [...]
GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year
16/04/2024
MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, is [...]
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
16/04/2024
WILMETTE, Ill., April 16, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced [...]
Vittoria Biotherapeutics Announces Keith Westby as Chief Operating Officer
16/04/2024
PHILADELPHIA, April 16, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage cell therapy company, has announced that Keith Westby has joined the company as its inaugural Chief Operating Officer. Mr. [...]
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
16/04/2024
The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a checkpoint blocker. [...]
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
16/04/2024
PRINCETON, N.J., April 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara Cloud, the unifying platform that integrates [...]
FountainRx Selects Inovalon’s ScriptMed® Software To Enhance Patient Care and Scale Specialty and Infusion Pharmacy Services
16/04/2024
ScriptMed Cloud-Based SaaS Software Enables Data-Driven Workflows and Provides More Personalized, Cost-Effective Care for Patients with Complex Health Conditions BOWIE, Md., April 16, 2024 (GLOBE NEWSWIRE) -- Inovalon [...]
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
16/04/2024
Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Danish Medicines [...]
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
16/04/2024
— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: [...]
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
16/04/2024
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and [...]

Pages